Audit: QRS - Shilajit for Health & Longevity
Audit conducted on 13/09/2026 08:59 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated span traces to ER text: protocol doses to ER Therapeutic Protocol, time-to-effect to ER Practical Considerations, benefit/risk tiers to the ER tier headings, all 14 markers and 7 qualitative items to the ER monitoring table and list. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | e.g. action_2_sub “1000 mg daily has been used for eight weeks without incident” and action_3_sub “not trial-derived, and dose accuracy is poor” mirror ER lines 342 and 344. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain contraindications (line 572 “Pregnant and breastfeeding women” under the Contraindications gate); no tier was promoted or demoted. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | stop_items draw solely from ER “Populations who should avoid Shilajit”; caution_items solely from the ER interaction bullets. No Benefit-Modifying Factors or Risk-Modifying Factors content appears. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, NCT identifiers, author names or brand names at all (PrimaVie, Natreon, ConsumerLab are all absent). |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | Only generic ER-sourced references (“the strength trial”, “the higher arm of the bone trial”, “the hormone, bone and skin trials”) appear, matching ER lines 340–342. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, sceptical register carried over from the ER Conclusion into at_a_glance. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Marker targets and doses are concrete and actionable while the framing stays neutral. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Statements are descriptive (“The dose used in the hormone, bone and skin trials”), not imperative. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | monitoring_cadence reports the ER’s own cadence wording rather than instructing the reader. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, “should” or “consult” anywhere in the document body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun (“you”, “your”) occurs in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are either unavoidable marker names or glossed as in the ER (“broken shinbone”, “filtration rate”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate items, benefit and risk lines carry no mechanistic rationale or citations. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by the same second-person scan as 2.6. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional marker ranges and lot-level contamination framing address exactly this audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | A 14-marker monitoring panel with a baseline-plus-12-week cadence assumes a high-effort audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content depth (transferrin saturation, urinary arsenic and thallium) is well beyond general-population material. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | at_a_glance foregrounds product quality as the dominant variable, the decision-relevant point for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the title uses “Health & Longevity” (line 22). |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No route-of-administration colloquialisms; “shinbone” and “rice-grain-sized portion” are the ER’s own wording (ER lines 480 and 344). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All headings match the template byte-for-byte (lines 446, 493, 542, 569, 591, 619, 641, 645–647, 850); tier labels “Medium”, “Low”, “Speculative” retained verbatim. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 27 named spans present; marker_#_* expanded to 1–14 and qualitative_item_# to 1–7. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against the template shows changes confined to frontmatter values and checklist-governed spans; website="evidence_review", website="audit" and website="full_review" are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section is empty; the unpopulated benefit/risk tiers are governed by 12.5 and 13.5, which mandate display:none instead of empty-state phrasing. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard regimen”, “Higher-dose variant”, “Traditional resin approach” match ER lines 340, 342, 344; interaction labels match ER lines 293–309. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names are verbatim from the ER biomarker table; time-to-effect labels use the ER’s own terms from line 399. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Scan for 🟩/🟥/🟨/⚠ returned nothing; the ER’s “⚠️ Conflicted” markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every free-text span is condensed to one or two lines; the remaining length is driven by the completeness requirements of 14.2 and 15.2. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: the metadata comment immediately follows <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no frontmatter value is echoed into visible markup other than the legitimately rendered date and model name. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:04" is quoted, correctly so because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: shilajit_2026-0913-0716_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0913-0848. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” = nickname plus version, no context-window or other qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s actual name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: Shilajit for Health & Longevity - Quick Reference Sheet. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: Shilajit for Health & Longevity, matching ER frontmatter canonical_topic. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/13/2026, correct reformatting of 2026-0913-0848. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5, identical to the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (lines 415–428) contains only the title and the template subline; the ER’s “Also known as” line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all three Conclusion paragraphs (ER lines 480–484) and closes on the execution-relevant point, product quality. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 55 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Three named signals → ER line 480; short-term tolerance → ER line 482; toxic metals and quality as dominant variable → ER lines 482 and 484. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “menopause”, “testosterone” and “shinbone” are everyday terms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | Only the generic “Controlled trials point to…”; no author, year, n or p-value. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No percentages, ranges or statistics appear. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items map to ER lines 313–318 (“Populations who should avoid Shilajit”). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All six ER avoid-populations are present, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 572–586: six well-formed <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Em-dash clauses stripped from the pregnancy and under-18 items; “the current reference value for elevation” stripped from the blood-lead item. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds retained: ferritin >300 ng/mL with TSAT >45%, blood lead ≥3.5 µg/dL, PSA >4 ng/mL, CKD stage 3b with the <45 mL/min/1.73 m² parenthetical, age <18. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s avoid list uses spelled-out comparators (“above”, “at or above”, “or worse”); no bare ranking symbols occur. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER does identify such populations and the section is correspondingly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items map one-to-one onto ER lines 293–309. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | No item duplicates a contraindication; all nine ER interaction bullets are represented. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 594–609: nine well-formed <li> elements. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The “Caution”/”Monitor” verdicts, mechanisms and mitigation sentences are all stripped; the acid-reducer item correctly drops the text after the em-dash. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All named drug lists preserved; the bisphosphonate parenthetical trimmed to “(alendronate, risedronate)” without losing the named examples. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction parentheticals are plain comma-separated drug lists; no ranking notation occurs. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies nine such interactions and all are carried over. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | The three cells correspond to the first three bullets of ER Therapeutic Protocol (lines 340–344). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard regimen, higher-dose variant and traditional resin approach are the three dosing decisions; the remaining ER bullets are contextual rather than actionable. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three or more actionable aspects and all three sets are populated. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans (lines 450–488) hold substantive ER-derived content; no placeholder remains. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Bone density, hormones and collagen/strength markers are exactly the three windows named in ER line 399. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Bone density and testosterone are the ER’s Medium-tier benefits and lead; collagen/strength markers, tied to the Low-tier strength finding, come last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names three distinct time-to-effect aspects and all three sets are populated. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans (lines 499–534) carry ER-sourced content; “nothing meaningful is assessable before three months” is verbatim from ER line 399. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Medium, Low and Speculative lines reproduce the ER’s own benefit headings (ER lines 147–203). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 544, 545, 551 and 557. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-separated list of bare benefit names; no magnitudes, p-values, trial descriptions or PMIDs carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | Line 544: benefits_high carries style="display: none" with no content, matching the ER’s “No benefit reaches High” (ER line 143). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Low and Speculative lines reproduce the ER’s seven risk headings (ER lines 237–273). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 621, 622, 623 and 630. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Bare risk names only; the thallium figures, case-report details and mechanistic glosses from the ER are omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks span; the ER’s pseudohyperaldosteronism parenthetical is dropped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | Lines 621–622: both risks_high and risks_medium are empty with style="display: none", matching ER lines 229 and 233. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table reproduces the ER Monitoring Protocol & Defining Success biomarker table (ER lines 431–446). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 14 ER biomarkers appear as marker_1 through marker_14, with targets and “why” text matching the ER cells. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 839–844 reproduce the ER’s cadence paragraph (ER lines 427 and 429): baseline, 12 weeks, then every 6 months, with the glucose and bone-scan caveats. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Items map to the ER’s “Qualitative markers worth tracking alongside the laboratory work” list (ER lines 450–456). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All seven ER qualitative markers appear verbatim as qualitative_item_1 through qualitative_item_7. |
Issues 13/09/2026 08:59
Pass rate 100.00%. No issues found.
Issues 13/09/2026 08:55
- 4.5 — Monitoring target cell not condensed:
marker_14_target(lines 825–828) carries the ER’s full 141-character explanatory sentence, roughly five wrapped lines in a 9pt table cell, where every other target cell is 42 characters or fewer — un-condensed against the one-page budget.
Fixes 13/09/2026 08:55
- 4.5 — Monitoring target cell condensed: Shortened
marker_14_targetfrom “No established target for supplement users; the informative measure is the change from an individual’s own pre-supplement baseline” to “No established target; change from own pre-supplement baseline”, bringing the cell in line with the other target cells and the one-page budget while keeping the ER’s cautious “no established target” framing.